Neurovance (Cambridge, MA), a clinical-stage pharmaceutical company focused on treatments for CNS disorders such as adult attention deficit hyperactivity disorder, closed a $7M Series A financing. Participants include Novartis Venture Fund. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP […]
BioBehavioral Diagnostics (Westford, MA) a commercial-stage diagnostics company focused on the Quotient™ ADHD System for the objective and accurate assessment of attention-deficit hyperactivity disorder, closed a $10M Series B financing. Participants include Sevin Rosen Funds and Tullis Health Investors.